Last Updated: June 12, 2026

Patent: 6,458,563


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,458,563
Title:Modified factor VIII
Abstract:The invention relates to a modified B-domainless form of porcine factor VIII, to a DNA encoding the same, and to the use thereof for treatment of hemophilia.
Inventor(s):John S. Lollar
Assignee: Emory University
Application Number:US09/523,656
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

United States Patent 6,458,563: Claim Strength, Validity Risk, and US Landscape

What is US Patent 6,458,563 and what does it claim?

US Patent 6,458,563 (issued Oct 1, 2002) is directed to [insufficient information in the record provided]. The claim set, independent claims, and key limitations are not present in the input provided here. Without the patent’s claims and specification excerpts, no complete or accurate claim-by-claim analysis can be produced, and no defensible conclusions on claim scope, novelty, obviousness, or enforceability can be made.

Why can’t the claim-level analysis be completed from the current inputs?

A comprehensive patent analysis requires at minimum:

  • the independent claims and their claim construction-critical phrases,
  • the preferred embodiments that anchor interpretation,
  • the prosecution history (e.g., amendments and rejections),
  • and the prior art that the examiner cited (and that challengers would use).

None of these elements are included in the prompt. Under the constraints, an incomplete answer cannot be produced.


Claim-Landscape Analytics That Require the Missing Claim Text

Which prior art would likely be mapped against each limitation?

This requires the actual claim limitations (elements), then a limitation-by-limitation mapping to:

  • cited references in the US prosecution,
  • non-cited but relevant publications and patents,
  • and the closest contemporaneous commercial products.

Without the claim text, there is no basis for a limitation mapping.

How strong are the independent claims versus dependent claims?

Strength depends on:

  • whether independent claims are functional or structural,
  • whether they include narrow ranges or broad genus language,
  • and whether dependent claims add meaningful, non-obvious features.

None of that can be assessed without the claim set.

What is the realistic litigation risk profile?

Risk depends on:

  • likely §101 posture (if software/biologics method claims exist),
  • §102 anticipation risk,
  • §103 obviousness risk based on claim breadth,
  • and enforceability issues tied to prosecution history estoppel.

These are not determinable without claims and file history.


Landscape Positioning and Competitive Relevance

What patents are most likely to overlap in scope in the US?

Landscape overlap requires:

  • identifying the technical field of the patent,
  • translating claim limitations into search terms,
  • then reviewing:
    • forward citations from the patent,
    • lateral citations from close art,
    • and active prosecution families with similar claim themes.

The patent’s subject matter and claim elements are not provided, so no reliable overlap assessment can be made.

What do forward citations imply about technical adoption?

Forward citations require the citation set for US 6,458,563. That citation record is not included in the input, so forward-citation-based conclusions cannot be made.

What does backward citation analysis indicate about novelty?

Backward citation analysis depends on:

  • listed references in the patent and prosecution,
  • which ones are most relevant to each independent claim,
  • and whether those references were distinguishable by argument or amendment.

No citation list is provided.


Key Takeaways

  • US Patent 6,458,563 cannot be analyzed at the claim and validity level from the information supplied in the prompt.
  • A comprehensive assessment requires the actual claim language, specification support, and citation/prosecution record. Without them, any “critical” evaluation would be speculative, which the constraints prohibit.
  • No landscape conclusions can be grounded without the patent’s technical domain and claim limitations.

FAQs

  1. Can you provide a claim-by-claim infringement analysis for US 6,458,563 without the claim text? No. Claim construction depends on the exact wording of independent and dependent claims.
  2. Can you assess §102/§103 validity risk for US 6,458,563 without knowing what the claims cover? No. Validity analysis requires mapping claim limitations to specific prior art.
  3. Can you identify overlapping patents in the US landscape without the patent’s technical field and claim scope? No. Overlap depends on claim-to-technology translation.
  4. Can you infer enforceability and prosecution history estoppel risk without the file wrapper? No. Estoppel depends on amendments and arguments during examination.
  5. Can you estimate commercial relevance from citations without the citation list? No. Forward and backward citation analysis needs the actual citation record.

References

[1] United States Patent 6,458,563 (issue date: Oct 1, 2002). (Source not provided in the prompt.)

More… ↓

⤷  Start Trial

Details for Patent 6,458,563

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Takeda Pharmaceuticals U.s.a., Inc. OBIZUR antihemophilic factor (recombinant), porcine sequence For Injection 125512 October 23, 2014 ⤷  Start Trial 2020-03-10
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.